Grace Therapeutics Announces 2026 Fiscal Year-End Financial Results, Provides Business Update

Type A Meeting Scheduled with FDA to Potentially Clarify Path to GTx-104 NDA Resubmission

Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.